What is Alzheimer’s disease?
Alzheimer’s disease is a progressive neurological disease that damages brain cells and the connections between them. Over time, it affects memory, thinking, language, judgment, behavior and the ability to manage everyday life. Alzheimer’s is the most common cause of dementia, but the two words are not interchangeable. Dementia describes a level of cognitive decline that interferes with daily functioning; Alzheimer’s is one specific disease that can cause it.
The changes associated with Alzheimer’s usually develop slowly. A person may first have trouble remembering recent conversations, keeping track of appointments or learning new information. Later, problems can expand into language, decision-making, orientation, behavior and basic daily activities. The pace varies from person to person, and symptoms are not identical in every family.
What happens in the brain?
Alzheimer’s involves several biological changes. Two of the best known are abnormal accumulations of beta-amyloid protein between brain cells and abnormal forms of tau protein inside brain cells. These changes are associated with inflammation, loss of communication between neurons and eventually the death of brain cells. Scientists continue to study how these processes interact and why they begin when they do.
Most Alzheimer’s disease begins after age 65, but younger-onset Alzheimer’s can occur. Age is the strongest known risk factor, yet Alzheimer’s is not a normal or inevitable part of aging. Genetics can influence risk, especially in rare families with specific inherited mutations, but most cases appear to reflect a combination of age, genetics, cardiovascular health and other biological or environmental factors.
Mild cognitive impairment and Alzheimer’s
Some people first receive a diagnosis of mild cognitive impairment, or MCI. MCI means thinking or memory has changed more than expected for age but daily independence is largely preserved. MCI has many possible causes. When it is related to Alzheimer’s biology, it can represent an early symptomatic stage of the disease, but MCI does not always progress to dementia.
Alzheimer’s and Down syndrome
People with Down syndrome have an increased biological risk of developing Alzheimer’s disease as they age because chromosome 21 carries the gene for amyloid precursor protein. Increased risk does not mean that every person with Down syndrome will develop dementia, and changes should still be evaluated rather than assumed to be Alzheimer’s.
Signs and symptoms of Alzheimer’s disease
Occasional forgetfulness is common. Alzheimer’s is different because the pattern becomes persistent, gradually worsens and begins to interfere with independence. Early symptoms are often subtle enough that people adapt around them for months or years before anyone realizes how much has changed.
Common signs can include:
- Increasing difficulty remembering recent information. A person may repeat questions, forget conversations or depend more heavily on notes and reminders for things they previously managed.
- Problems with planning and problem-solving. Bills, recipes, travel arrangements or tasks with several steps may become unusually difficult.
- Getting lost or disoriented. Familiar routes may become confusing, or a person may lose track of dates, seasons or where they are.
- Language changes. Finding words, following conversation, reading or writing may become harder.
- Poor judgment. Financial decisions, personal safety or responses to scams may change.
- Changes in mood or behavior. A person may become withdrawn, anxious, suspicious, irritable or less flexible than before.
- Difficulty recognizing people or completing self-care. These changes are more common as the disease advances.
Not every memory problem is Alzheimer’s
Memory problems can also result from depression, medication effects, sleep problems, thyroid disease, vitamin deficiencies, infections, substance use, stroke and other neurological conditions. Sudden confusion is especially important because Alzheimer’s usually develops gradually. A rapid change in attention or awareness may be delirium, which can signal an urgent medical problem.
Depression can also affect concentration, motivation and memory. If sadness, loss of interest or hopelessness are prominent, evaluation for major depressive disorder may be part of the workup. A person can have depression and Alzheimer’s at the same time.
Diagnosis and tests
There is no single office test that tells the whole story. Diagnosis usually begins with a detailed history from the person and, when possible, someone who knows them well. A provider asks when changes started, how they have progressed and which daily activities have become harder.
Evaluation may include tests of memory, language, attention, problem-solving and other cognitive skills; a neurological and physical exam; blood or urine testing to look for potentially reversible causes; and brain imaging such as MRI or CT. Depression screening and medication review are also common because both can influence cognition.
Biomarkers
Alzheimer’s biomarkers are becoming increasingly important. Depending on the clinical setting and availability, specialists may use cerebrospinal fluid tests, PET scans or certain blood tests that detect patterns associated with amyloid or tau. These tools can increase diagnostic confidence, especially when disease-modifying treatment is being considered. A biomarker result still needs to be interpreted in the context of symptoms and the rest of the evaluation.
Why earlier diagnosis can matter
An early diagnosis gives people more opportunity to participate in decisions about treatment, finances, driving, work, legal planning and future care. It can also reduce the exhausting uncertainty that families sometimes experience when everyone sees changes but no one has a name for them yet.
Bring the real-life examples
People often perform better in a quiet clinic than they do while managing a complicated week at home. When you seek an evaluation, bring concrete examples: two missed mortgage payments, getting lost driving to a familiar store, leaving a burner on or forgetting the same conversation several times in a day. Those examples help translate a test score into actual function.
It is also useful to bring a complete medication list and information about hearing, vision, sleep and alcohol use. Each can affect cognition, and correcting a contributing problem can improve function even when Alzheimer’s is present.
Treatment for Alzheimer’s disease
There is currently no treatment that cures Alzheimer’s disease or restores brain cells that have already been lost. Treatment can, however, help some symptoms, support daily functioning and, for some people in the early stages with confirmed amyloid pathology, modestly slow disease progression.
Medicines for symptoms
Cholinesterase inhibitors such as donepezil, rivastigmine, galantamine and benzgalantamine may help cognitive symptoms for some people with mild to moderate Alzheimer’s. Memantine may be used in moderate to severe disease. These medicines do not stop the underlying disease, but they may support thinking or daily function for a period of time.
Disease-modifying treatments
Anti-amyloid medicines such as lecanemab and donanemab are used for selected people with early symptomatic Alzheimer’s disease who meet specific criteria. They can slow decline for some patients but are not appropriate for everyone. Treatment requires confirmation of amyloid and careful monitoring for side effects, including amyloid-related imaging abnormalities that can involve brain swelling or bleeding. Decisions about these medicines belong with clinicians experienced in Alzheimer’s treatment.
Care beyond medication
Regular routines, physical activity as medically appropriate, treatment of hearing or vision problems, good sleep, social connection and management of cardiovascular risk factors can support overall function. Occupational therapy, home-safety changes and caregiver education may become increasingly important as the disease progresses.
Behavior changes such as agitation, sleep disruption or paranoia should be evaluated for triggers including pain, infection, medication effects, overstimulation or unmet needs. The goal is not simply to sedate behavior. It is to understand what the person may be communicating through it.
Safety planning changes over time
Driving, cooking, medication management and living alone may be safe at one stage and unsafe at another. These decisions are easier when families discuss them before a crisis. A driving evaluation, occupational therapy assessment or home-safety review can replace arguments based only on fear or pride with information about actual function.
Outlook
Alzheimer’s is progressive. Symptoms become more significant over time, although the rate of change is unpredictable. Some people remain relatively stable for periods and then decline more quickly; others experience a steadier progression. Eventually, most people need increasing help with medication management, meals, transportation, finances, personal care and safety.
Progression does not erase personhood. Preferences, humor, comfort, relationships and emotional responses can remain meaningful even when memory and language are changing. Good care pays attention to quality of life, not only cognitive scores.
Caregiving is part of the clinical picture
Alzheimer’s affects families as well as the person diagnosed. Caregivers may experience chronic stress, grief, sleep disruption, financial strain and isolation. Accepting respite care, home health support, adult day services, counseling or family help is not abandoning the person. Sustainable caregiving usually requires more than one set of hands.
Living with Alzheimer’s disease
In early stages, many people continue to participate in work, hobbies, family life and decision-making. Simple systems can reduce frustration: keeping important items in consistent places, using calendars and medication organizers, simplifying financial tasks and planning transportation before driving becomes unsafe.
For families
Correcting every mistaken detail can turn ordinary interactions into constant conflict. When safety is not at stake, it may be more helpful to respond to the emotion underneath the statement than to win the factual argument. Speak directly to the person, allow extra time for responses and avoid discussing them as if they are not in the room.
Sudden worsening should not automatically be blamed on Alzheimer’s. New confusion, sleepiness, agitation, falls or loss of function may signal infection, medication effects, dehydration, pain or delirium and should be medically evaluated.
A note from Project Semicolon
An Alzheimer’s diagnosis can make the future feel as if it arrived all at once. There are medical decisions, family decisions and practical decisions, but you do not have to solve every year of the disease in the first week.
Start with what matters now: a clear evaluation, a treatment plan, the people you trust and the next decisions that truly need to be made. Memory may change over time, but dignity should not become negotiable. The person living with Alzheimer’s is still a person first, and care should keep making room for that.
